Drug Trial Radar · NCT00858871
First Line Hepato Cellular Carcinoma (HCC)
Last checked: Nov 20, 2026Latest source record: Oct 17, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,714
Actual
Start
May 2009
Primary completion
Jun 2012
Study completion Sep 2013
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Conditions
- Hepato Cellular Carcinoma (HCC)
Interventions
BrivanibDrug
Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
PlaceboDrug
Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
SorafenibDrug
Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
PlaceboDrug
Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatmentTime frame: Survival will be assessed continuously
Locations
173 sites in 26 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona
Univ Of Ark For Med Sci
Little Rock, Arkansas
Agajanian Institute Of Hematology And Oncology
Downey, California
Sharp Clinical Oncology Research
San Diego, California
Va Ct Healthcare System
West Haven, Connecticut
Medical Specialists Of Palm Beaches
Lake Worth, Florida
James Graham Brown Cancer Center
Louisville, Kentucky
3912 Taubman Center
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Thomas Jefferson Univ.
Philadelphia, Pennsylvania
Mcguire Dvamc
Richmond, Virginia
University Of Wisconsin
Madison, Wisconsin
Local Institution
Buenos Aires, Buenos Aires, Argentina
Local Institution
Caba, Buenos Aires, Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina
Local Institution
Rosario, Santa Fe Province, Argentina
Local Institution
Camperdown, New South Wales, Australia
Local Institution
Concord, New South Wales, Australia
Local Institution
Westmead Nsw, New South Wales, Australia
Local Institution
Parkville, Victoria, Australia
Local Institution
Prahan, Victoria, Australia
Local Institution
Liège, Belgium
Local Institution
Fortaleza, Ceará, Brazil
Local Institution
Salvador, Estado de Bahia, Brazil
Local Institution
Salvador - Ba, Estado de Bahia, Brazil
Local Institution
Goiânia, Goiás, Brazil
Local Institution
Divinópolis, Minas Gerais, Brazil
Local Institution
Curitiba, Paraná, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Barretos, São Paulo, Brazil
Local Institution
Jaú, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
Calgary, Alberta, Canada
Local Institution
Vancouver, British Columbia, Canada
Local Institution
London, Ontario, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Beijing, Beijing Municipality, China
Local Institution
Beijing, Beijing Municipality, China
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.